Clinical update on nursing home medicine: 2011

Journal of the American Medical Directors Association

Volumn 12, Issue 9, 2011, Pages

  Messinger Rapport, Barbara J ^a   Morley, John E ^b   Thomas, David R ^b   Gammack, Julie K ^b  

^a LERNER RESEARCH INSTITUTE   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticoagulants; Delirium; Diabetes mellitus; Osteoporosis; Polypharmacy; Proton pump inhibitors; Weight loss

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ACETYLSALICYLIC ACID; ALPHA GLUCOSIDASE INHIBITOR; ANTIDIABETIC AGENT; BISPHOSPHONIC ACID DERIVATIVE; CLOPIDOGREL; DABIGATRAN; DENOSUMAB; DIPEPTIDYL PEPTIDASE IV INHIBITOR; HISTAMINE H2 RECEPTOR ANTAGONIST; HUMAN INSULIN; IBANDRONIC ACID; INSULIN DERIVATIVE; INSULIN GLARGINE; ISOPHANE INSULIN; METFORMIN; OMEPRAZOLE; PARACETAMOL; PROTON PUMP INHIBITOR; ROSIGLITAZONE; SITAGLIPTIN; SODIUM CHANNEL STIMULATING AGENT; SULFONYLUREA DERIVATIVE; THIOCTIC ACID; THROMBIN INHIBITOR; TOPIRAMATE; UNINDEXED DRUG; VILDAGLIPTIN; WARFARIN; ZOLEDRONIC ACID;

ANOREXIA; ANTICOAGULANT THERAPY; ARTICLE; BARE METAL STENT; BLEEDING; BONE DENSITY; BRAIN HEMORRHAGE; CLOSTRIDIUM DIFFICILE INFECTION; COMMUNITY ACQUIRED PNEUMONIA; DELIRIUM; DIABETES MELLITUS; DIABETIC DIET; DIET SUPPLEMENTATION; DRUG ELUTING STENT; DRUG ERUPTION; FOOD INTAKE; GASTROESOPHAGEAL REFLUX; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HIP FRACTURE; HUMAN; HYPOGLYCEMIA; HYPOTENSION; LOADING DRUG DOSE; MUSCLE ATROPHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; NURSING HOME; OSTEOPOROSIS; PERIPHERAL NEUROPATHY; POLYPHARMACY; RECURRENT DISEASE; RISK FACTOR; SECONDARY PREVENTION; SEDENTARY LIFESTYLE; SIDE EFFECT; SINUS RHYTHM; SPINE FRACTURE; STENT THROMBOSIS; STRESS ULCER; STROKE; TERMINAL CARE; TRANSIENT ISCHEMIC ATTACK; TREMOR; VITAMIN BLOOD LEVEL; WEIGHT REDUCTION;

EID: 82455219551     PISSN: 15258610     EISSN: 15389375     Source Type: Journal    
DOI: 10.1016/j.jamda.2011.08.007     Document Type: Article

References (267)

1. Morley J.E. Osteoporosis and fragility fractures. J Am Med Dir Assoc 2011, 12:389-392.
2. Miles R.W. Hip fracture reduction in northwest Arkansas nursing homes. J Am Med Dir Assoc 2008, 9:449-453.
3. Gloth F.M., Simonson W. Osteoporosis is underdiagnosed in skilled nursing facilities: a large-scale heel BMD screening study. J Am Med Dir Assoc 2008, 9:190-193.
4. Kamel H.K. Update on Osteoporosis management in long-term care: Focus on bisphosphonates. J Am Med Dir Assoc 2007, 8:434-440.
5. Heinrich S., Rapp K., Rissmann U., et al. Service use and costs of incident femoral fractures in nursing home residents in Germany: The Bavarian fall and fracture prevention project (BG(2)P(2)). J Am Med Dir Assoc 2011, 12:459-466.
6. Young Y., Xiong K., Pruzek R.M., Brant L.J. Examining heterogeneity of functional recovery among older adults with hip fractures. J Am Med Dir Assoc 2010, 11:132-139.
7. Curtis J.R., Arora T., Matthews R.S., et al. Is withholding osteoporosis medication after fracture sometimes rational? A comparison of the risk for second fracture versus death. J Am Med Dir Assoc 2010, 11:584-591.
8. Jalbert J.J., Eaton C.B., Miller S.C., et al. Antipsychotic use and the risk of hip fracture among older adults afflicted with dementia. J Am Med Dir Assoc 2010, 11:120-127.
9. Lapcevic W.A., French D.D., Campbell R.R. All-cause mortality rates of hip fractures treated in the VHA: Do they differ from Medicare facilities?. J Am Med Dir Assoc 2010, 11:116-119.
10. Zimmerman S., Magaziner J., Birge S.J., et al. Adherence to hip protectors and implications for U.S. long-term care settings. J Am Med Dir Assoc 2010, 11:106-115.
11. Nelson H.D., Haney E.M., Chou R., et al. Screening for Osteoporosis: Systematic Review to Update the 2002 U.S. Preventive Services Task Force Recommendation July 2010, Agency for Healthcare Research and Quality, U.S. Department of Health and Human Services, Rockville, MD, Number 77.
12. Miller P.D. Diagnosis and treatment of osteoporosis in chronic renal disease. Semin Nephrol 2009, 29(2):144-155.
13. Black D.M., Kelly M.P., Genant H.K., et al. Bisphosphonates and fractures of the subtrochanteric or diaphyseal femur. N Engl J Med 2010, 362(19):1761-1771.
14. Park-Wyllie L.Y., Mamdani M.M., Juurlink D.N., et al. Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 2011, 305(8):783-789.
15. Cummings S.R., San Martin J., McClung M.R., et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009, 361(8):756-765.
16. Smith M.R., Egerdie B., Hernandez Toriz N., et al. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med 2009, 361(8):745-755.
17. Islam T., Peiris P., Copeland R.J., et al. Vitamin D: Lessons from the veterans population. J Am Med Dir Assoc 2011, 12:257-262.
18. Demontiero O., Herrmann M., Duque G. Supplementation with vitamin D and calcium in long-term care residents. J Am Med Dir Assoc 2011, 12:190-194.
19. Grant W.B., Peiris A.N. Possible role of serum 25-hydroxyvitamin D in black-white health disparities in the United States. J Am Med Dir Assoc 2010, 11:617-628.
20. Gaddipati V.C., Kuriacose R., Copeland R., et al. Vitamin D deficiency: an increasing concern in peripheral arterial disease. J Am Med Dir Assoc 2010, 11:308-311.
21. Gau J.T. Prevalence of vitamin D deficiency/insufficiency practice patterns in nursing homes. J Am Med Dir Assoc 2010, 11:296.
22. Peiris A.N., Bailery B., Manning T., et al. Testing for vitamin D deficiency in veterans-is there a seasonal bias?. J Am Med Dir Assoc 2010, 11:128-131.
23. Braddy K.K., Imam S.N., Palla K.R., et al. Vitamin D deficiency/insuffiency practice patterns in a veterans Health Administration long-term care population: a retrospective analysis. J Am Med Dir Assoc 2009, 10:653-657.
24. Drinka P.J., Krause P.F., Nest L.J., et al. Determinants of vitamin D levels in nursing home residents. J Am Med Dir Assoc 2007, 8:76-79.
25. Hamid Z., Riggs A., Spencer T., et al. Vitamin D deficiency in residents of academic long-term care facilities despite having been prescribed vitamin D. J Am Med Dir Assoc 2007, 8:71-75.
26. Bischoff-Ferrari H.A., Willett W.C., Wong J.B., et al. Prevention of nonvertebral fractures with oral vitamin D and dose dependency: A meta-analysis of randomized controlled trials. Arch Intern Med 2009, 169(6):551-561.
27. Sanders K.M., Stuart A.L., Williamson E.J., et al. Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial. JAMA 2010, 303(18):1815-1822.
28. Curhan G.C., Willett W.C., Speizer F.E., et al. Comparison of dietary calcium with supplemental calcium and other nutrients as factors affecting the risk for kidney stones in women. Ann Intern Med 1997, 126(7):497-504.
29. Giovannucci E., Liu Y., Stampfer M.J., Willett W.C. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiol Biomark Prev 2006, 15(2):203-210.
30. Bolland M.J., Avenell A., Baron J.A., et al. Effect of calcium supplements on risk of myocardial infarction and cardiovascular events: meta-analysis. BMJ 2010, 341:c3691.
31. Bolland M.J., Grey A., Avenell A., et al. Calcium supplements with or without vitamin D and risk of cardiovascular events: reanalysis of the Women's Health Initiative limited access dataset and meta-analysis. BMJ 2011, 342:d2040.
32. Reid I.R., Bolland M.J., Avenell A., et al. Cardiovascular effects of calcium supplementation. Osteoporo Int 2011, 22(6):1649-1658.
33. Anderson G.L., Limacher M., Assaf A.R., et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial [see comment]. JAMA 2004, 291(14):1701-1712.
34. Rossouw J.E., Anderson G.L., Prentice R.L., et al. Risk and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative Randomized Controlled Trial. JAMA 2002, 288(3):321-333.
35. Shumaker S.A., Legault C., Thal L., et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women: the Women's Health Initiative Memory Study: a randomized controlled trial [comment]. JAMA 2003, 289(20):2651-2662.
36. Kanis J.A., McCloskey E.V., Johansson H., et al. Development and use of FRAX in osteoporosis. Osteoporo Int 2010, 21(Suppl 2):S407-S413.
37. Zhang X., Decker F.H., Luo H., et al. Trends in the prevalence and comorbidities of diabetes in nursing home residents in the United States: 1995-2004. J Am Geriatr Soc 2010, 58:724-730.
38. Gerstel C., Zarate Laguines M., Vischer U.M. Fecal incontinence resolved using metformin withdrawal. J Am Geriatr Soc 2011, 59:756-757.
39. Mazza A.D., Morley J.E. Update on diabetes in the elderly and the application of current therapeutics. J Am Med Dir Assoc 2007, 8:489-492.
40. Lu F.P., Lin K.P., Kuo H.K. Diabetes and the risk of multi-system phenotypes: a systematic review and meta-analysis. PLoS One 2009, 4:e4144. Epub 2009 Jan 7.
41. Meyers R.M., Reger L. Diabetes management in long-term care facilities: a practical guide. J Am Med Dir Assoc 2009, 10:589.
42. Luchsinger J.A., Palmas W., Teresi J.A., et al. Improved diabetes control in the elderly delays global cognitive decline. J Nutr Health Aging 2011, 15:445-449.
43. van der Maarel-Wierink C.D., Vanobbergen J.N., Bronkhorst E.M., et al. Risk factors for aspiration pneumonia in frail older people: a systematic literature review. J Am Med Dir Assoc 2011, 12:344-354.
44. Chen L.K., Peng L.N., Lin M.H., et al. Diabetes mellitus, glycemic control, and pneumonia in long-term care facilities: a 2-year, prospective cohort study. J Am Med Dir Assoc 2011, 12:33-37.
45. Schwartz A.V., Vittinghoff E., Bauer D.C., et al. Association of BMD and FRAX score with risk of fracture in older adults with type 2 diabetes. JAMA 2011, 305:2184-2192.
46. Rosenthal M.J., Fajardo M., Gilmore S., et al. Hospitalization and mortality of diabetes in older adults. A 3-year prospective study. Diabetes Care 1998, 21:231-235.
47. Miller D.K., Lui L.Y., Perry H.M., et al. Reported and measured physical functioning in older inner-city diabetic African Americans. J Gerontol A Biol Sci Med Sci 1999, 54:M230-M236.
48. Morley J.E. Diabetes and aging: epidemiologic overview. Clin Geriatr Med 2008, 24:395-405.
49. Vischer U.M. Glycemic targets for elderly diabetic patients need reappraisal. J Am Med Dir Assoc 2011, 12:9-11.
50. Bourdel-Marchasson I., Doucet J., Bauduceau B., et al. Key priorities in managing glucose control in older people with diabetes. J Nutr Health Aging 2009, 13:685-691.
51. Paolisso G., Sinclair A.J. Effective clinical practice for older people with type 2 diabetes. Glucose regulation is important but other strategies also need to be included. J Nutr Health Aging 2010, 14:3-4.
52. Morley J.E. Hypertension: Is it overtreated in the elderly?. J Am Med Dir Assoc 2010, 11:147-152.
53. Morley J.E. Editorial: Postprandial hypotension-the ultimate Big Mac Attack. J Gerontol A Biol Sci Med Sic 2001, 56:M741-M743.
54. Iwanczyk L., Weintraub N.T., Rubenstein L.Z. Orthostatic hypotension in the nursing home setting. J Am Med Dir Assoc 2006, 7:163-167.
55. Gentilcore D., Vanis L., Wishart J.M., et al. The alpha-glucosidase inhibitor, acarbose, attenuates the blood pressure and splanchnic blood flow responses to intraduodenal sucrose in older adults. J Gerontol A Biol Sci Med Sci 2011, May 31 [Epub ahead of print].
56. Lee A. Preventive treatment with acarbose in diabetic reactive hypoglycemia. J Am Med Dir Assoc 2010, 11:377-378.
57. Maxwell C.S., Wood R.J. Update on vitamin D and type 2 diabetes. Nutr Rev 2011, 69:291-295.
58. Morley J.E. Vitamin D redux. J Am Med Dir Assoc 2009, 10:591-592.
59. Jin H.Y., Joung S.J., Park J.H., et al. The effect of alpha-lipoic acid on symptoms and skin blood flow in diabetic neuropathy. Diabet Med 2007, 24:1034-1038.
60. Foster T.S. Efficacy and safety of alpha-lipoic acid supplementation in the treatment of symptomatic diabetic neuropathy. Diabetes Educ 2007, 33:111-117.
61. Bouillet B., Vaillant G., Petit J.M., et al. Are elderly patients with diabetes being overtreated in French long-term-care homes?. Diabetes Metab 2010, 36:272-277.
62. Mooradian A.D., Osterweil D., Petrasek D., et al. Diabetes mellitus in elderly nursing home patients. A survey of clinical characteristics and management. J Am Geriatr Soc 1988, 36:391-396.
63. Joseph J., Koka M., Aronow W.S. Prevalence of a hemoglobin A1C less than 7.0%, of a blood pressure less than 130/80 mm Hg, and of a serum low-density lipoprotein cholesterol less than 100 mg/dL in older patients with diabetes mellitus in an academic nursing home. J Am Med Dir Assoc 2008, 9:51-54.
64. Gersteain H.C., Miller M.E., Genuth S., et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828. ACCORD Study Group.
65. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358:2560-2572. ADVANCE Collaborative Group.
66. Duckworth W., Abraira C., Moritz T., et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009, 360:129-139.
67. Currie C.J., Peters J.R., Rynan A., et al. Survival as a function of HbA(1c) in people with type 2 diabetes: a retrospective cohort study. Lancet 2010, 375:481-489.
68. Nelson J.M., Dufraux K., Cook P.F. The relationship between glycemic control and falls in older adults. J Am Geriatr Soc 2007, 55:2041-2044.
69. Wedick N.M., Barrett-Connor E., Knoke J.D., et al. The relationship between weight loss and all-cause mortality in older men and women with and without diabetes mellitus: The Rancho Bernardo study. J Am Geriatr Soc 2002, 50:1810-1815.
70. Coulston A.M., Mandelbaum D., Reaven G.M. Dietary management of nursing home residents with non-insulin-dependent diabetes mellitus. Am J Clin Nutr 1990, 51:67-71.
71. Tariq S.H., Karcic E., Thomas D.R., et al. The use of a no-concentrated-sweets diet in the management of type 2 diabetes in nursing homes. J Am Diet Assoc 2001, 101:1463-1466.
72. Dorner B., Friedrich E.K., Posthauer M.E. Practice paper of the american dietetic association: Individualized nutrition approaches for older adults in health care communities. J Am Diet Assoc 2010, 110(10):1554-1563.
73. 1c levels in type 2 diabetes: a systematic review and meta-analysis. JAMA 2011, 305:1790-1799.
74. Morley J.E. The elderly type 2 diabetic patient: special considerations. Diabet Med 1998, (15 Suppl 4):S41-S46.
75. Colberg S.R., Somma C.T., Sechrist S.R. Physical activity participation may offset some of the negative impact of diabetes on cognitive function. J Am Med Dir Assoc 2008, 9:434-438.
76. Aman E., Thomas D.R. Supervised exercise reduces agitation in severely cognitively impaired persons. J Am Med Dir Assoc 2009, 10:271-276.
77. Rolland Y., Abellan van Kan G., Vellas B. Physical activity and Alzheimer's disease: from prevention to therapeutic perspectives. J Am Med Dir Assoc 2008, 9:390-405.
78. Colberg S.R., Zarrabi L., Bennington L., et al. Postprandial walking is better for lowering the glycemic effect of dinner than pre-dinner exercise in type 2 diabetic individuals. J Am Med Dir Assoc 2009, 10:394-397.
79. Nylen E.S., Kokkinos P., Myers J., et al. Prognostic effect of exercise capacity on mortality in older adults with diabetes mellitus. J Am Geriatr Soc 2010, 58:1850-1854.
80. Morley J.E., Mooradian A.D., Rosenthal M.J., et al. Diabetes mellitus in elderly patients. Is it different?. Am J Med 1987, 83:533-544.
81. Holman R. Metformin as first choice in oral diabetes treatment: The UKPDS experience. J Annu Diabetol Hotel Dieu 2007, 13-20.
82. Kumar V.B., Bernardo A.E., Vyas K., et al. Effect of metformin on nitric oxide synthase in genetically obese (ob/ob) mice. Life Sci 2001, 69:2789-3799.
83. Lee A., Morley J.E. Metformin decreases food consumption and induces weight loss in subjects with obesity with type II non-insulin-dependent diabetes. Obes Res 1998, 6:47-53.
84. Messinger-Rapport B.J., Thomas D.R., et al. Clinical update on nursing home medicine: 2008. J Am Med Dir Assoc 2008, 9:460-475.
85. Viccica G., Francucci C.M., Marcocci C. The role of PPARy for the osteoblastic differentiation. J Endocrinol Invest 2010, 33(7 Suppl):9-12.
86. Vestergaard P. Bone metabolism in type 2 diabetes and role of thiazolidinediones. Curr Opin Endocrinol Diabetes Obes 2009, 16:125-131.
87. Kahn S.E., Zinman B., Lachin J.M., et al. Rosiglitazone-associated fractures in type 2 diabetes: an analysis from a Diabetes Outcome Progression Trial (ADOPT). Diabetes Care 2008, 31:845-851.
88. Lee A., Patrick P., Wishart J., et al. The effects of miglitol on glucagon-like peptide-1 secretion and appetite sensations in obese type 2 diabetics. Diabetes Obes Metab 2002, 4:329-335.
89. DeLeon M.J., Chandurkar V., Albert S.G., et al. Glucagon-like peptide-1 response to acarbose in elderly type 2 diabetic subjects. Diabetes Res Clin Pract 2002, 56:101-106.
90. Stafford S., Elahi D., Meneilly G.S. Effect of the dipeptidyl peptidase-4 inhibitor sitagliptin in older adults with type 2 diabetes mellitus. J Am Geriatr Soc 2011, 1148-1149.
91. Schejter Y.D., Turvall E., Ackerman Z. Characteristics of patients with sulphonurea-induced hypoglycemia. J Am Med Dir Assoc 2010, 10.1016/j.jamda.2010.07.014.
92. Pandya N., Nathanson E. Managing diabetes in long-term care facilities: benefits of switching from human insulin to insulin analogs. J Am Med Dir Assoc 2010, 11:171-178.
93. Yki-Jarvinen H., Kauppinen-Makelin R., Tiikkainen M., et al. Insulin glargine or nph combined with metformin in type 2 diabetes: The LANMET study. Diabetologia 2006, 49(3):442-451.
94. Fritsche A., Schweitzer M.A., Haring H.U. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. A randomized, controlled trial. Ann Intern Med 2003, 138(12):952-959.
95. Rosenstock J., Schwartz S.L., Clark C.M., et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001, 24(4):631-636.
96. Kumari J., Dharmarajan T.S. Insulin glargine induced persistent intractable hypoglycemia, with variable presentations in older diabetic patients: an experience of 4 cases. J Am Med Dir Assoc 2009, 10:672-673.
97. Morley J.E. Polypharmacy in the nursing home. J Am Med Dir Assoc 2009, 10:289-291.
98. Fitzgerald S.P., Bean N.G. An analysis of the interactions between individual comorbidities and their treatments-implications for guidelines and polypharmacy. J Am Med Dir Assoc 2010, 11:475-484.
99. Gokce Kutsal Y., Barak A., Atalay A., et al. Polypharmacy in the elderly: a multicenter study. J Am Med Dir Assoc 2009, 10:486-490.
100. Messinger-Rapport B.J., Morley J.E., Thomas D.R., et al. Clinical update on nursing home medicine: 2010. J Am Med Dir Assoc 2010, 11:543-566.
101. Chisholm J.W., Goldfine A.B., Dhalia A.K., et al. Effect of ranolazine on A1C and glucose levels in hyperglycemic patients with non-ST elevation acute coronary syndrome. Diabetes Care 2010, 33:1163-1168.
102. Strojek K., Yoon K., Hruba V., et al. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial. Diabetes Obes Metab 2011, Jun 15 [Epu ahead of print].
103. Feldman S.M., Rosen R., DeStasio J. Status of diabetes management in the nursing home setting in 2008: a retrospective chart review and epidemiology study of diabetic nursing home residents and nursing home initiatives in diabetes management. J Am Med Dir Assoc 2009, 10:354-360.
104. Gerstein H.C., Miller M.E., Byington R.P., et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008, 358(24):2545-2559.
105. Patel A., MacMahon S., Chalmers J., et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008, 358(24):2560-2572.
106. Reaven P.D., Moritz T.E., Schwenke D.C., et al. Intensive glucose lowering therapy reduces cardiovascular disease events in VADT participants with lower calcified coronary atherosclerosis. Diabetes Aug 3 2009.
107. 1c. Endocr Pract 2006, 12(Suppl 1):42-46.
108. Pandya N., Thompson S., Sambamoorthi U. The prevalence and persistence of sliding scale insulin use among newly admitted elderly nursing home residents with diabetes mellitus. J Am Med Dir Assoc 2008, 9(9):663-669.
109. Castellanos V.H., Andrews Y.N. Inherent flaws in a method of estimating meal intake commonly used in long-term-care facilities. J Am Diet Assoc 2002, 102(6):826-830.
110. Thomas D.R., Ashmen W., Morley J.E., et al. Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. Am J Clin Nutr 2002, 75:308-313.
111. Morley J.E. Anorexia and weight loss in older persons. J Gerontol A Biol Sci Med Sci 2003, 58:131-137.
112. Kalantar-Zadeh K., Horwich T.B., Oreopoulos A., et al. Risk factor paradox in wasting diseases. Curr Opin Clin Nutr Metab Care 2007, 10:433-442.
113. Karcic E., Philpot C., Morley J.E. Treating malnutrition with megestrol acetate: literature review and review of our experience. J Nutr Health Aging 2002, 6:191-200.
114. Payette H. Nutrition as a determinant of functional autonomy and quality of life in aging: a research program. Can J Physiol Pharmacol 2005, 83:1061-1070.
115. Ensrud K.E., Ewing S.K., Stone K.L., et al. Intentional and unintentional weight loss increase bone loss and hip fracture risk in older women. J Am Geriatr Soc 2003, 51:1740-1747.
116. Morley J.E. Undernutrition: a major problem in nursing homes. J Am Med Dir Assoc 2011, 12:243-246.
117. Tolson D., Rolland Y., Andrieu S., et al. International Association of Gerontology and Geriatrics: A global agenda for clinical research and quality of care in nursing homes. J Am Med Dir Assoc 2011, 12:184-189.
118. Morley J.E. Anorexia, weight loss, and frailty. J Am Med Dir Assoc 2010, 11:225-228.
119. Murphy C. The chemical senses and nutrition in older adults. J Nutr Elder 2008, 27:247-265.
120. Jones K.L., Doran S.M., Hveem K., et al. Relation between postprandial satiation and antral area in normal subjects. Am J Clin Nutr 1997, 66:127-132.
121. Sturm K., Parker B., Wishart J., et al. Energy intake and appetite are related to antral area in healthy young and older subjects. Am J Clin Nutr 2004, 80:656-667.
122. MacIntosh C.G., Morley J.E., Wishart J., et al. Effect of exogenous cholecystokinin (CCK)-8 on food intake and plasma CCK, leptin, and insulin concetrations in older and young adults: evidence for increased CCK activity as a cause of the anorexia of aging. J Clin Endocrinol Metab 2001, 86:5830-5837.
123. Sih R., Morley J.E., Kaiser F.E., et al. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997, 82:1661-1667.
124. Gosnell B.A., Levine A.S., Morley J.E. The effects of aging on opioid modulation of feeding in rats. Life Sci 1983, 32:2793-2799.
125. Morley J.E., Levine A.S. The pharmacology of eating behavior. Annu Rev Pharmacol Toxicol 1985, 25:127-146.
126. Cornali C., Franzoni S., Frisoni G.B., et al. Anorexia as an independent predictor of mortality. J Am Geriatr Soc 2005, 53:354-355.
127. Morley J.E. Weight loss in older persons: new therapeutic approaches. Curr Pharm Des 2007, 13:3637-3647.
128. Wilson M.M., Thomas D.R., Rubenstein L.Z., et al. Appetite assessment: simple appetite questionnaire predicts weight loss in community-dwelling adults and nursing home residents. Am J Clin Nutr 2005, 82:1074-1081.
129. Morley J.E. Assessment of malnutrition in older persons: A focus on the Mini Nutritional Assessment. J Nutr Health Aging 2011, 15:87-90.
130. Vellas B., Villars H., Abellan G., et al. Overview of the MNA-Its history and challenges. J Nutr Health Aging 2006, 10:456-463.
131. Charlton K.E., Nichols C., Bowden S., et al. Older rehabilitation patients are at high risk of malnutrition: evidence from a large Australian database. J Nutr Health Aging 2010, 14:622-628.
132. Kaiser M.J., Bauer J.M., Ramsch C., et al. Validation of the Mini Nutritional Assessment short-form (MNA-SF): A practical tool for identification of nutritional status. J Nutr Health Aging 2009, 13:782-788.
133. Abellan van Kan G., Rolland Y., Bergman H., et al. The I.A.N.A. Task Force on frailty assessment of older people in clinical practice. J Nutr Health Aging 2008, 12:29-37.
134. Abellan van Kan G., Rolland Y.M., Morley J.E., et al. Frailty: Toward a clinical definition. J Am Med Dir Assoc 2008, 9:71-72.
135. Omran M.L., Morley J.E. Assessment of protein energy malnutrition in older persons, Part II: Laboratory evaluation. Nutrition 2000, 16:131-140.
136. Morley J.E., Kraenzle D. Causes of weight loss in a community nursing home. J Am Geriatr Soc 1988, 36:487-491.
137. Morley J.E. Depression in nursing home residents. J Am Med Dir Assoc 2010, 11:301-303.
138. Cabrera M.A., Mesas A.E., Garcia A.R., et al. Malnutrition and depression among community-dwelling elderly people. J Am Med Dir Assoc 2007, 8:582-584.
139. Argiles J.M., Anker S.D., Evans W.J., et al. Consensus on cachexia definitions. J Am Med Dir Assoc 2010, 11:229-230.
140. Evans W.J., Morley J.E., Argiles J., et al. Cachexia: A new definition. Clin Nutr 2008, 27:793-799.
141. Morley J.E., Thomas D.R., Wilson M.M. Cachexia: pathophysiology and clinical relevance. Am J Clin Nutr 2006, 83:735-743.
142. Morley J.E., Thomas D.R. Cachexia: new advances in the management of wasting diseases. J Am Med Dir Assoc 2008, 9:205-210.
143. von Haehling S., Anker S.D. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachex Sarcopenia Muscle 2010, 1:1-5.
144. von Haehling S., Anker S.D. Cardio-renal anemia syndrome. Contrib Nephrol 2011, 171:266-273.
145. Yeh S.S., Blackwood K., Schuster M.W. The cytokine basis of cachexia and its treatment: are they ready for prime time?. J Am Med Dir Assoc 2008, 9:219-236.
146. von Haehling S., Morley J.E., Anker S.D. An overview of sarcopenia: facts and numbers on prevalence and clinical impact. J Cachex Sarcopenia Muscle 2010, 1:129-133.
147. Morley J.E., Baumgartner R.N., Roubenoff R., et al. Sarcopenia. J Lab Clin Med 2001, 137:231-243.
148. Morley J.E., Abbatecola A.M., Argiles J.M., et al. Sarcopenia with limited mobility: An international consensus. J Am Med Dir Assoc 2011, 12:403-409.
149. Fielding R.A., Vellas B., Evans W.J., et al. Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International Working Group on Sarcopenia. J Am Med Dir Assoc 2011, 12:249-256.
150. Cruz-Jentoft A.J., Baevens J.P., Bauer J.M., et al. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing 2010, 39:412-423.
151. Baumgartner R.N., Wayne S.J., Waters D.L., et al. Sarcopenic obesity predicts instrumental activities of daily living disability in the elderly. Obes Res 2004, 12:1995-2004.
152. Rolland Y., Lauwers-Cances V., Cristini C., et al. Difficulties with physical function associated with obesity, sarcopenia, and sarcopenic-obesity in community-dwelling elderly women: the EPIDOS (EPIDemiologie de l'OSteoporose) Study. Am J Clin Nutr 2009, 89:1895-1900.
153. Thomas D.R., Cote T.R., Lawhorne L., et al. Understanding clinical dehydration and its treatment. J Am Med Dir Assoc 2008, 9:292-301.
154. Messinger-Rapport B.J., Thomas D.R., Gammack J.K., et al. Clinical update on nursing home medicine: 2009. J Am Med Dir Assoc 2009, 10:530-553.
155. Thomas D.R., Ashmen W., Morley J.E., et al. Nutritional management in long-term care: development of a clinical guideline. Council for Nutritional Strategies in Long-Term Care. J Gerontol A Biol Sci Med Sci 2000, 55:M725-M734.
156. Nijs K., de Graaf C., van Staveren W.A., et al. Malnutrition and mealtime ambiance in nursing homes. J Am Med Dir Assoc 2009, 10:226-229.
157. Morley J.E. Weight loss in the nursing home. J Am Med Dir Assoc 2007, 8:201-204.
158. Milne A.C., Potter J., Vivanti A., et al. Protein and energy supplementation in elderly people at risk from malnutrition. Cochrane Database Syst Rev 2009, (2):CD003288.
159. Wilson M.M., Punushothaman R., Morley J.E. Effect of liquid dietary supplements on energy intake in the elderly. Am J Clin Nutr 2001, 75:944-947.
160. van Wetering C.R., Hoogendoorn M., Broekhuizen R., et al. Efficacy and costs of nutritional rehabilitation in muscle-wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup analysis of the INTERCOM trial. J Am Med Dir Assoc 2010, 11:179-187.
161. Neelemaat F., Bosmans J.E., Thijs A., et al. Post-discharge nutritional support in malnourished elderly individuals improves functional limitations. J Am Med Dir Assoc 2011, 12:295-301.
162. Morley J.E., Argiles J.M., Evans W.J., et al. Nutritional recommendations for the management of sarcopenia. J Am Med Dir Assoc 2010, 11:391-396.
163. Chapman I.M., MacIntosh C.G., Morley J.E., et al. The anorexia of aging. Biogerontology 2002, 3:67-71.
164. Yeh S.S., Lovitt S., Schuster M.W. Usage of megestrol acetate in the treatment of anorexia-cachexia syndrome in the elderly. J Nutr Health Aging 2009, 13:448-454.
165. Yeh S., Wu S.Y., Levine D.M., et al. Quality of life and stimulation of weight gain after treatment with megestrol acetate: correlation between cytokine levels and nutritional status, appetite in geriatric patients with wasting syndrome. J Nutr Health Aging 2000, 4:246-251.
166. Wilson M.M., Philpot C., Morley J.E. Anorexia of aging in long-term care: is dronabinol an effective appetite stimulant?-a pilot study. J Nutr Health Aging 2007, 11:195-198.
167. Jatoi A., Windschitl H.E., Loprinzi C.L., et al. Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: A North Central Cancer Treatment Group study. J Clin Oncol 2002, 20:567-573.
168. Wang C., Nieschlag E., Swerdloff R., et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM EAU, EAA and ASA recommendations. Eur J Endocrinol 2008, 159:507-514.
169. Morley J.E. Anabolic steroids and frailty. J Am Med Dir Assoc 2010, 11:533-536.
170. Chahla E.J., Hayek M.E., Morley J.E. Testosterone replacement therapy and cardiovascular risk factors modification. Aging Male 2011, 14:83-90.
171. Basaria S., Coviello A.D., Travison T.G., et al. Adverse events associated with testosterone administration. N Engl J Med 2010, 363:109-122.
172. Chapman I.M., Visvanathan R., Hammond A.J., et al. Effect of testosterone and a nutritional supplement, alone and in combination, on hospital admissions in undernourished older men and women. Am J Clin Nutr 2009, 89:880-889.
173. Srinivas-Shankar U., Roberts S.A., et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010, 95:639-650.
174. Bhasin S., Jasuja R. Selective androgen receptor modulators as function promoting therapies. Curr Opin Clin Nutr Metab Care 2009, 12:232-240.
175. Cheung W.W., Mak R.H. Ghrelin and its analogues as therapeutic agents for anorexia and cachexia in end-stage renal disease. Kidney Int 2009, 76:135-137.
176. Chasen M., Hirschman S.Z., Bhargava R. Phase II study of the novel peptide-nucleic acid OHR118 in the management of cancer-related anorexia/cachexia. J Am Med Dir Assoc 2011, 12:62-67.
177. Kuo S., Rhodes R.L., Mitchell S.L., et al. Natural history of feeding-tube use in nursing home residents with advanced dementia. J Am Med Dir Assoc 2009, 10:264-270.
178. Gillick M.R., Volandes A.E. The standard of caring: why do we still use feeding tubes in patients with advanced dementia?. J Am Med Dir Assoc 2008, 9:364-367.
179. Beier M.T. Warfarin monitoring woes: a glimmer of hope with pharmacogenomics. J Am Med Dir Assoc 2008, 9:199-200.
180. Dharmarajan L., Sajjad W. Potentially lethal acetaminophen-warfarin interaction in an older adult: an under-recognized phenomenon?. J Am Med Dir Assoc 2007, 8:545-547.
181. Gurwitz J.H. Pharmacogenomics: Is this the final chapter in the remarkable story of warfarin?. J Am Med Dir Assoc 2011, May 13 [Epub ahead of print].
182. Dharmarajan T.S., Gupta A., Baig M.A., et al. Warfarin: Implementing its safe use in hospitalized patients from nursing homes and community through a performance improvement initiative. J Am Med Dir Assoc 2011, 12:613-614.
183. Aguilar M.I., et al. Cochrane Database Syst Rev 2007, (3):CD00618.
184. Saxena R., Koudstaal P.J. Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev 2006, (1):CD000187.
185. Gage B.F., Waterman A.D., Shannon W., et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001, 285:2864-2870.
186. Connolly S.J., Ezekowitz M.D., Yusuf S., et al. RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
187. Man-Son-Hing M., et al. Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls. Arch Intern Med 1999, 159:677-685.
188. Massie B.M., Krol W.F., Ammon S.E., et al. The Warfarin and Antiplatelet Therapy in Heart Failure trial (WATCH): rationale, design, and baseline patient characteristics. J Card Fail 2004, 10(2):101-112.
189. Cleland J.G., Findlay I., Jafri S., et al. The Warfarin/Aspirin Study in Heart failure (WASH): a randomized trial comparing antithrombotic strategies for patients with heart failure. Am Heart J 2004, 148(1):157-164.
190. Bhatt D.L., Fox K.A., Hacke W., et al. Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006, 354:1706-1717. CHARISMA Investigators.
191. Hankey G.J., Hacke W., Easton J.D., et al. Effect of clopidogrel on the rate and functional severity of stroke among high vascular risk patients: a prespecified substudy of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA) trial. Stroke 2010, 41(8):1679-1683. CHARISMA Trial Investigators.
192. Squizzato A., et al. Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular disease. Cochrane Database Syst Rev 2007, (3):CD005158.
193. Grines C.L., Bonow R.O., Casey D.E., et al. Prevention of premature discontinuation of dual antiplatelet therapy in patients with coronary artery stents. Circulation 2007, 115:813-818. American Heart Association, American College of Cardiology, Society for Cardiovascular Angiography and Interventions, American College of Surgeons, American Dental Association, American College of Physicians.
194. Mehta S.R., Yusuf S., Peters R.J., et al. Clopidogrel in Unstable angina to prevent Recurrent Events trial (CURE) Investigators. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358(9281):527-533.
195. Price M.J., Berger P.B., Teirstein P.S., et al. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA 2011, 305:1079. GRAVITAS Investigators.
196. Rostom A., Dube C., Wells G.A., et al. Prevention of NSAID-induced gastroduodenal ulcers. Cochrane Database Syst Rev (11) 2010.
197. Cook D.J., Fuller H.D., Guyatt G.H., et al. Risk factors for gastrointestinal bleeding in critically ill patients. Canadian Critical Care Trials Group. N Engl J Med 1994, 330(6):377-381.
198. Kantorova I., Svoboda P., Scheer P., et al. Stress ulcer prophylaxis in critically ill patients: a randomized controlled trial. Hepato-Gastroenterology 2004, 51(57):757-761.
199. Yildizdas D., Yapicioglu H., Yilmaz H.L. Occurrence of ventilator-associated pneumonia in mechanically ventilated pediatric intensive care patients during stress ulcer prophylaxis with sucralfate, ranitidine, and omeprazole. J Crit Care 2002, 17:240-245.
200. Lin P.C., Chang C.H., Hsu P.I., et al. The efficacy and safety of proton pump inhibitors vs histamine-2 receptor antagonists for stress ulcer bleeding prophylaxis among critical care patients: A meta-analysis. Crit Care Med 2010, 38:1197.
201. Barletta J.F., Erstad B.L., Fortune J.B. Stress ulcer prophylaxis in trauma patients. Crit Care (London, England) 2002, 6(6):526-530.
202. Lam N.P., Le P.D., Crawford S.Y., Patel S. National survey of stress ulcer prophylaxis. Crit Care Med 1999, 27:98-103.
203. Spirt M.J., Stanley S. Update on stress ulcer prophylaxis in critically ill patients. Crit Care Nurse 2006, 26:18-20. 22-28.
204. Martin R.M., Lim A.G., Kerry S.M., et al. Trends in prescribing H2-receptor antagonists and proton pump inhibitors in primary care. Aliment Pharmacol Ther 1998, 12(8):797-805.
205. The Medical Letter on Drugs and Therapeutics, February 23, 2009 (Issue 1306) p. 13.
206. Bhatt D.L., Cryer B.L., Contant C.F., et al. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med 2010, 363(20):1909-1917. COGENT Investigators.
207. Rodriguez L.A., Ruigomez A., Wallander M.A., et al. Acid-suppressive drugs and community-acquired pneumonia. Epidemiology 2009, 20(6):800-806.
208. Laheij R.J., Sturkenboom M.C., Hassing R.J., et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004, 292:1955-1960.
209. Gulmez S.E., Holm A., Frederiksen H., et al. Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. Arch Intern Med 2007, 167:950-955.
210. Vestergaard P., Rejnmark L., Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calc Tiss Int 2006, 79(2):76-83.
211. Targownik L.E., Lix L.M., Metge C.J., et al. Use of PPIs and risk of osteoporosis-related fracture. CMAJ 2008, 179(4):319-326.
212. Dial S., Kezouh A., Dascal A., et al. Patterns of antibiotic use and risk of hospital admission because of Clostridium difficile infection. CMAJ 2008, 179(8):767-772.
213. Kazakova S.V., Ware K., Baughman B., et al. A hospital outbreak of diarrhea due to an emerging epidemic strain of Clostridium difficile. Arch Intern Med 2006, 166(22):2518-2524.
214. Leonard J., Marshall J.K., Moayyedi P. Systematic review of the risk of enteric infection in patients taking acid suppression. Am J Gastroenterol 2007, 102:2047-2205.
215. Al-Tureihi F.I., Hassoun A., Wolf-Klein G., et al. Albumin, length of stay, and proton pump inhibitors: key factors in Clostridium difficile-associated disease in nursing home patients. J Am Med Dir Assoc 2005, 6(2):105-108.
216. McColl E.L. Am J Gastroenterol 2009, 104:S5-S9.
217. Hutchison C. Proton pump inhibitors suppress absorption of dietary non-heme iron in hereditary haemochromatosis. Gut 2007, 56:1291-1295.
218. Sharma V.R., Brannon M.A., Carloss E.A. Effect of omeprazole on oral iron replacement in patients with iron deficiency anemia. South Med J 2004, 97:887-889.
219. Hoover J.G., et al. Use of intravenous proton-pump inhibitors in a teaching hospital practice. Dig Dis Sci 2009, 54:1947-1952.
220. Bellelli G., Magnifico F., Trabucchi M. Outcomes at 12 months in a population of elderly patients discharged from a rehabilitation unit. J Am Med Dir Assoc 2008, 9(1):55-64.
221. Witlox J., Eurelings L.S., de Jonghe J.F., et al. Delirium in elderly patients and the risk of postdischarge mortality, institutionalization, and dementia: a meta-analysis. JAMA 2010, 304(4):443-451.
222. Guerini F., Frisoni G.B., Morghen S., et al. Clinical instability as a predictor of negative outcomes among elderly patients admitted to a rehabilitation ward. J Am Med Dir Assoc 2010, 11(6):443-448.
223. Bellelli G., Speciale S., Morghen S., et al. Are fluctuations in motor performance a diagnostic sign of delirium?. J Am Med Dir Assoc 2011, 12:578-583.
224. Francis J., Martin D., Kapoor W.N. A prospective study of delirium in hospitalized elderly. JAMA 1990, 263(8):1097-1101.
225. Inouye S.K., Viscoli C.M., Horwitz R.I., et al. A predictive model for delirium in hospitalized elderly medical patients based on admission characteristics. Ann Intern Med 1993, 119(6):474-481.
226. Inouye S.K. Delirium in hospitalized older patients: recognition and risk factors. J Geriatr Psychiatry Neurol 1998, 11(3):118-125. discussion 157-158.
227. Lewis L.M., Miller D.K., Morley J.E., et al. Unrecognized delirium in ED geriatric patients. Am J Emerg Med 1995, 13(2):142-145.
228. Flaherty J.H., Shay K., Weir C., et al. The development of a mental status vital sign for use across the spectrum of care. J Am Med Dir Assoc 2009, 10(6):379-380.
229. Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Author, Washington, DC. Revised 4th ed.
230. Inouye S.K., van Dyck C.H., Alessi C.A., et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med 1990, 113(12):941-948.
231. Flaherty J.H. Psychotherapeutic agents in older adults. Commonly prescribed and over-the-counter remedies: causes of confusion. Clin Geriatr Med 1998, 14(1):101-127.
232. van Munster B.C., Korevaar J.C., Zwinderman A.H., et al. The association between delirium and the apolipoprotein E epsilon 4 allele: new study results and a meta-analysis. Am J Geriatr Psychiatry 2009, 17(10):856-862.
233. van Munster B.C., de Rooij S.E., Yazdanpanah M., et al. The association of the dopamine transporter gene and the dopamine receptor 2 gene with delirium, a meta-analysis. Am J Med Genet B Neuropsychiatr Genet 2010, 153B(2):648-655.
234. von Gunten A., Mosimann U.P. Delirium upon admission to Swiss nursing homes: a cross-sectional study. Swiss Med Wkly 2010, 140(25-26):376-381.
235. Voyer P., Richard S., Doucet L., et al. Detecting delirium and subsyndromal delirium using different diagnostic criteria among demented long-term care residents. J Am Med Dir Assoc 2009, 10(3):181-188.
236. Dosa D., Intrator O., McNicoll L., et al. Preliminary derivation of a Nursing Home Confusion Assessment Method based on data from the Minimum Data Set. J Am Geriatr Soc 2007, 55(7):1099-1105.
237. Kiely D.K., Jones R.N., Bergmann M.A., et al. Association between psychomotor activity delirium subtypes and mortality among newly admitted post-acute facility patients. J Gerontol A Biol Sci Med Sci 2007, 62(2):174-179.
238. Gamberini M., Bolliger D., Lurati Buse G.A., et al. Rivastigmine for the prevention of postoperative delirium in elderly patients undergoing elective cardiac surgery-a randomized controlled trial. Crit Care Med 2009, 37(5):1762-1768.
239. Overshott R., Vernon M., Morris J., et al. Rivastigmine in the treatment of delirium in older people: a pilot study. Int Psychogeriatr 2010, 22(5):812-818.
240. van Eijk M.M., Roes K.C., Honing M.L., et al. Effect of rivastigmine as an adjunct to usual care with haloperidol on duration of delirium and mortality in critically ill patients: a multicentre, double-blind, placebo-controlled randomised trial. Lancet 2010, 376(9755):1829-1837.
241. Sampson E.L., Raven P.R., Ndhlovu P.N., et al. A randomized, double-blind, placebo-controlled trial of donepezil hydrochloride (Aricept) for reducing the incidence of postoperative delirium after elective total hip replacement. Int J Geriatr Psychiatry 2007, 22(4):343-349.
242. Schneider L.S., Dagerman K.S., Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005, 294(15):1934-1943.
243. Tahir T.A., Eeles E., Karapareddy V., et al. A randomized controlled trial of quetiapine versus placebo in the treatment of delirium. Psychosom Res 2010, 69(5):485-490.
244. Larsen K.A., Kelly S.E., Stern T.A., et al. Administration of olanzapine to prevent postoperative delirium in elderly joint-replacement patients: a randomized, controlled trial. Psychosomatics 2010, 51(5):409-418.
245. Lonergan E., Britton A.M., Luxenberg J., et al. Antipsychotics for delirium. Cochrane Database Syst Rev 2007, (2):CD005594.
246. Lundström M., Olofsson B., Stenvall M., et al. Postoperative delirium in old patients with femoral neck fracture: a randomized intervention study. Aging Clin Exp Res 2007, 19(3):178-1786.
247. Chen J.S., Simpson J.M., March L.M., et al. Fracture risk assessment in frail older people using clinical risk factors. Age Ageing 2008, 37(5):536-541.
248. Nguyen J.K., Fouts M.M., Kotabe S.E., et al. Polypharmacy as a risk factor for adverse drug reactions in geriatric nursing home residents. Am J Geriatr Pharmacother 2006, 4:36-41.
249. Morley J.E. Conundrums of polypharmacy. Aging Successfully 2003, 13(2):1-2.
250. Van Bruggen R., Gorter K., Stolk R.P., et al. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. Pharmacoepidemiol Drug Saf 2009, 18(11):983-991.
251. Beers M.H., Ouslander J.G., Rollingher I., et al. Explicit criteria for determining inappropriate medication use in nursing home residents. Arch Intern Med 1991, 151(9):1825-1832.
252. Beers M.H. Explicit criteria for determining potentially inappropriate medication use by the elderly. An update. Arch Intern Med 1997, 157(14):1531-1536.
253. Fick D.M., Cooper J.W., Wade W.E., et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003, 163(22):2716-2724.
254. Stuart B., Kamal-Bahl S., Briesacher B., et al. Trends in the prescription of inappropriate drugs for the elderly between 1995 and 1999. Am J Geriatr Pharmacother 2003, 1(2):61-74.
255. Curtis L.H., Østbye T., Sendersky C., et al. Inappropriate prescribing for elderly Americans in a large outpatient population. Arch Intern Med 2004, 164(15):1621-1625.
256. Sloane P.D., Zimmerman S., Brown L.C., et al. Inappropriate medication prescribing in residential care/assisted living facilities. J Am Geriatr Soc 2002, 50(6):1001-1011.
257. Zhan C., Sangl J., Bierman A.S., et al. Potentially inappropriate medication use in the community-dwelling elderly: findings from the 1996 Medical Expenditure Panel Survey. JAMA 2001, 286(22):2823-2829.
258. Swagerty D., Brickley R. American Medical Directors Association and American Society of Consultant Pharmacists joint position statement on the Beers List of Potentially Inappropriate Medications in Older Adults. J Am Med Dir Assoc 2005, 6(1):80-86.
259. Lund B.C., Carnahan R.M., Egge J.A., et al. Inappropriate prescribing predicts adverse drug events in older adults. Ann Pharmacother 2010, 44(6):957-963.
260. Ryan C., O'Mahony D., Kennedy J., et al. Potentially inappropriate prescribing in an Irish elderly population in primary care. Br J Clin Pharmacol 2009, 68(6):936-947.
261. Bregnhøj L., Thirstrup S., Kristensen M.B., et al. Combined intervention programme reduces inappropriate prescribing in elderly patients exposed to polypharmacy in primary care. Eur J Clin Pharmacol 2009, 65(2):199-207.
262. Vinks T.H., Egberts T.C., de Lange T.M., et al. Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging 2009, 26(2):123-133.
263. Laroche M.L., Charmes J.P., Nouaille Y., et al. Impact of hospitalisation in an acute medical geriatric unit on potentially inappropriate medication use. Drugs Aging 2006, 23(1):49-59.
264. Terrell K.M., Perkins A.J., Dexter P.R., et al. Computerized decision support to reduce potentially inappropriate prescribing to older emergency department patients: a randomized, controlled trial. J Am Geriatr Soc 2009, 57(8):1388-1394.
265. Simon S.R., Smith D.H., Feldstein A.C., et al. Computerized prescribing alerts and group academic detailing to reduce the use of potentially inappropriate medications in older people. J Am Geriatr Soc 2006, 54(6):963-968.
266. Raebel M.A., Charles J., Dugan J., et al. Randomized trial to improve prescribing safety in ambulatory elderly patients. J Am Geriatr Soc 2007, 55(7):977-985.
267. Pit S.W., Byles J.E., Cockburn J. Medication Review: Patient selection and general practitioner's report of drug-related problems and actions taken in elderly Australians. J Am Geriatr Soc 2007, 55(6):927-934.